RetinalGenix Technologies to Participate at the 37th Annual Roth Conference
RetinalGenix Technologies (OTCQB:RTGN) announced its participation in the 37th Annual Roth Conference from March 16th to 18th, 2025, at The Laguna Cliffs Marriott in Dana Point, CA.
The company will showcase its RetinalCam™, a proprietary high-resolution, real-time retinal and ocular imaging system currently in the prototype stage and actively imaging patients. This technology aims to detect early biomarkers that could prevent potential blindness or systemic disease. RetinalGenix projects to complete testing by Q2 2025, with initial device sales expected later that year.
Additionally, the company is developing its DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software for validating and guiding novel therapeutic product development. CEO Jerry Katzman, MD, will be available for one-on-one meetings on March 17th and 18th during the conference, which is recognized as one of the premier investor events in the U.S.
RetinalGenix Technologies (OTCQB:RTGN) ha annunciato la sua partecipazione alla 37ª Conferenza Annuale Roth, che si svolgerà dal 16 al 18 marzo 2025 presso il Laguna Cliffs Marriott a Dana Point, CA.
L'azienda presenterà il suo RetinalCam™, un sistema proprietario di imaging retinico e oculare ad alta risoluzione e in tempo reale, attualmente in fase prototipale e attivamente utilizzato per l'imaging dei pazienti. Questa tecnologia mira a rilevare biomarcatori precoci che potrebbero prevenire la cecità potenziale o malattie sistemiche. RetinalGenix prevede di completare i test entro il secondo trimestre del 2025, con le prime vendite del dispositivo attese per la fine dell'anno.
Inoltre, l'azienda sta sviluppando il suo software DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ per convalidare e guidare lo sviluppo di nuovi prodotti terapeutici. Il CEO Jerry Katzman, MD, sarà disponibile per incontri individuali il 17 e 18 marzo durante la conferenza, riconosciuta come uno dei principali eventi per investitori negli Stati Uniti.
RetinalGenix Technologies (OTCQB:RTGN) anunció su participación en la 37ª Conferencia Anual Roth que se llevará a cabo del 16 al 18 de marzo de 2025 en el Laguna Cliffs Marriott en Dana Point, CA.
La compañía presentará su RetinalCam™, un sistema de imagen retiniana y ocular de alta resolución y en tiempo real, actualmente en fase de prototipo y que está imaging pacientes activamente. Esta tecnología tiene como objetivo detectar biomarcadores tempranos que podrían prevenir la ceguera potencial o enfermedades sistémicas. RetinalGenix proyecta completar las pruebas para el segundo trimestre de 2025, con las primeras ventas del dispositivo esperadas para más tarde ese año.
Además, la compañía está desarrollando su software DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ para validar y guiar el desarrollo de nuevos productos terapéuticos. El CEO Jerry Katzman, MD, estará disponible para reuniones individuales el 17 y 18 de marzo durante la conferencia, que es reconocida como uno de los principales eventos para inversores en EE. UU.
RetinalGenix Technologies (OTCQB:RTGN)은 2025년 3월 16일부터 18일까지 캘리포니아 다나 포인트의 라구나 클리프스 메리어트에서 열리는 제37회 연례 로스 회의에 참여한다고 발표했습니다.
회사는 현재 프로토타입 단계에 있으며 환자 이미징을 활발히 진행하고 있는 고해상도 실시간 망막 및 안구 이미징 시스템인 RetinalCam™을 선보일 예정입니다. 이 기술은 잠재적인 실명이나 전신 질환을 예방할 수 있는 조기 바이오마커를 감지하는 것을 목표로 하고 있습니다. RetinalGenix는 2025년 2분기까지 테스트를 완료할 계획이며, 그 해 말에 초기 장치 판매가 예상됩니다.
또한, 회사는 새로운 치료 제품 개발을 검증하고 안내하기 위한 DNA/RNA/GPS™ 약물유전학 매핑™ 소프트웨어를 개발하고 있습니다. CEO인 제리 카츠만 박사(MD)는 회의 기간 동안 3월 17일과 18일에 일대일 회의에 참석할 수 있습니다. 이 회의는 미국에서 가장 주요한 투자자 행사 중 하나로 인정받고 있습니다.
RetinalGenix Technologies (OTCQB:RTGN) a annoncé sa participation à la 37e Conférence Annuelle Roth, qui se tiendra du 16 au 18 mars 2025 au Laguna Cliffs Marriott à Dana Point, CA.
L'entreprise présentera son RetinalCam™, un système d'imagerie rétinienne et oculaire haute résolution en temps réel, actuellement en phase prototype et en cours d'imagerie de patients. Cette technologie vise à détecter des biomarqueurs précoces pouvant prévenir la cécité potentielle ou des maladies systémiques. RetinalGenix prévoit de terminer les tests d'ici le deuxième trimestre 2025, avec des ventes initiales de dispositifs attendues plus tard dans l'année.
De plus, l'entreprise développe son logiciel DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ pour valider et guider le développement de nouveaux produits thérapeutiques. Le PDG Jerry Katzman, MD, sera disponible pour des réunions individuelles les 17 et 18 mars lors de la conférence, qui est reconnue comme l'un des principaux événements pour investisseurs aux États-Unis.
RetinalGenix Technologies (OTCQB:RTGN) hat seine Teilnahme an der 37. jährlichen Roth-Konferenz angekündigt, die vom 16. bis 18. März 2025 im Laguna Cliffs Marriott in Dana Point, CA, stattfindet.
Das Unternehmen wird sein RetinalCam™ präsentieren, ein proprietäres hochauflösendes Echtzeit-System für die Bildgebung der Netzhaut und der Augen, das sich derzeit in der Prototypenphase befindet und aktiv Patienten im Bildverlauf aufnimmt. Diese Technologie zielt darauf ab, frühe Biomarker zu erkennen, die potenzielle Blindheit oder systemische Krankheiten verhindern könnten. RetinalGenix plant, die Tests bis zum 2. Quartal 2025 abzuschließen, wobei die ersten Geräteverkäufe noch in diesem Jahr erwartet werden.
Darüber hinaus entwickelt das Unternehmen seine DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ Software zur Validierung und Anleitung der Entwicklung neuartiger therapeutischer Produkte. CEO Jerry Katzman, MD, wird am 17. und 18. März während der Konferenz für Einzelgespräche zur Verfügung stehen, die als eines der führenden Investorenereignisse in den USA anerkannt ist.
- None.
- None.
Company will discuss its patented remote monitoring high-resolution retinal imaging system RetinalCam™ and associated biomarker technologies
APOLLO BEACH, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), today announced it will participate at the 37th Annual Roth Conference on March 16th to 18th. The Company will highlight its proprietary high-resolution, real-time retinal and ocular imaging and monitoring RetinalCam™, which is currently imaging patients and is in the prototype stage. RetinalCam™ may facilitate the detection of early biomarkers that could prevent possible future blindness or systemic disease. The Company is projecting to complete testing by Q2 2025, with the first device sales later in the year. RetinalGenix is also advancing its DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software to validate and guide the development of novel methods and therapeutic products.
Jerry Katzman, MD, CEO of RetinalGenix Technologies, will be in attendance during the conference and will be available for 1-on-1 meetings on March 17th and 18th. Interested investors should contact their ROTH representative or submit a registration request at Roth25Registration.
The Roth event is one of the premier investor conferences in the U.S., bringing together institutional investors, industry leaders, and emerging growth companies. The conference is being held at The Laguna Cliffs Marriott in Dana Point, CA. To learn more, visit www.roth.com/conferences/upcoming-conferences.
About RetinalGenix Technologies Inc.
RetinalGenix Technologies Inc. is an innovative ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. Its proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia. By integrating genetic screening, advanced imaging, and therapeutic development, RetinalGenix is positioned to become a leader in precision medicine.
For more information, visit RetinalGenix Technologies website.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, the Company can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond the Company's control), assumptions and other factors that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results may differ materially from those in the forward-looking statements and the trading price for the Company's common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company's filings with the SEC. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact:
(800) 331-5446
FAQ
When will RetinalGenix (RTGN) begin selling its RetinalCam device?
What is the current development stage of RTGN's RetinalCam technology?
What are the main applications of RetinalGenix's RetinalCam technology?
When and where is RetinalGenix (RTGN) presenting at the Roth Conference?
What additional technology is RetinalGenix developing besides RetinalCam?
